The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease?
|
|---|---|
| Published in |
Frontiers in Aging Neuroscience, August 2014
|
| DOI | 10.3389/fnagi.2014.00216 |
| Pubmed ID | |
| Authors |
Zhong Ming Qian, Ya Ke |
| Abstract |
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which there is no cure. Huperzine A (HupA) is a natural inhibitor of acetylcholinesterase (AChE) derived from the Chinese folk medicine Huperzia serrata (Qian Ceng Ta). It is a licensed anti-AD drug in China and is available as a nutraceutical in the US. A growing body of evidence has demonstrated that HupA has multifaceted pharmacological effects. In addition to the symptomatic, cognitive-enhancing effect via inhibition of AChE, a number of recent studies have reported that this drug has "non-cholinergic" effects on AD. Most important among these is the protective effect of HupA on neurons against amyloid beta-induced oxidative injury and mitochondrial dysfunction as well as via the up-regulation of nerve growth factor and antagonizing N-methyl-d-aspartate receptors. The most recent discovery that HupA may reduce brain iron accumulation lends further support to the argument that HupA could serve as a potential disease-modifying agent for AD and also other neurodegenerative disorders by significantly slowing down the course of neuronal death. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 2 | 13% |
| United States | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 12 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 94% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| India | 1 | <1% |
| Unknown | 112 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 13% |
| Student > Master | 15 | 13% |
| Researcher | 12 | 11% |
| Student > Bachelor | 12 | 11% |
| Professor > Associate Professor | 7 | 6% |
| Other | 21 | 18% |
| Unknown | 32 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 11% |
| Medicine and Dentistry | 12 | 11% |
| Chemistry | 11 | 10% |
| Agricultural and Biological Sciences | 9 | 8% |
| Neuroscience | 9 | 8% |
| Other | 21 | 18% |
| Unknown | 39 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2024.
All research outputs
#1,436,572
of 26,495,046 outputs
Outputs from Frontiers in Aging Neuroscience
#347
of 5,719 outputs
Outputs of similar age
#13,825
of 247,895 outputs
Outputs of similar age from Frontiers in Aging Neuroscience
#6
of 80 outputs
Altmetric has tracked 26,495,046 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,719 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,895 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.